Novo Nordisk A/S $NVO Shares Bought by Private Advisory Group LLC

Key Points

• Private Advisory Group LLC increased its stake in Novo Nordisk by 25.4% in Q4, buying 47,198 shares to hold 233,014 shares valued at about $11.856 million.
• FDA approved Awiqli (insulin icodec), the first once‑weekly basal insulin for adults with type 2 diabetes, positioning Novo Nordisk for a U.S. launch in the second half of 2026.
• Novo Nordisk beat quarterly estimates with $1.01 EPS (vs. $0.90 expected) and $12.43B revenue, but analyst views are mixed (consensus "Hold", average price target $65.56) while the stock trades near its 12‑month low around $36.

Private Advisory Group LLC grew its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 25.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 233,014 shares of the company's stock after purchasing an additional 47,198 shares during the period. Private Advisory Group LLC's holdings in Novo Nordisk A/S were worth $11,856,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. Revolve Wealth Partners LLC grew its stake in Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock worth $214,000 after buying an additional 200 shares during the period. AQR Capital Management LLC raised its stake in shares of Novo Nordisk A/S by 21.0% in the 1st quarter. AQR Capital Management LLC now owns 62,099 shares of the company's stock valued at $4,312,000 after acquiring an additional 10,758 shares during the period. Sivia Capital Partners LLC lifted its holdings in shares of Novo Nordisk A/S by 18.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company's stock valued at $712,000 after acquiring an additional 1,587 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Novo Nordisk A/S by 3.2% during the 2nd quarter. Rhumbline Advisers now owns 65,556 shares of the company's stock valued at $4,525,000 after acquiring an additional 2,017 shares in the last quarter. Finally, Grantham Mayo Van Otterloo & Co. LLC boosted its position in Novo Nordisk A/S by 63.7% during the 2nd quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 61,585 shares of the company's stock worth $4,251,000 after purchasing an additional 23,968 shares during the period. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock opened at $36.01 on Monday. Novo Nordisk A/S has a 12-month low of $35.85 and a 12-month high of $81.44. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The company has a market capitalization of $160.78 billion, a price-to-earnings ratio of 10.38, a price-to-earnings-growth ratio of 8.52 and a beta of 0.73. The firm's fifty day moving average price is $45.92 and its 200 day moving average price is $50.42.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating analysts' consensus estimates of $0.90 by $0.11. The company had revenue of $12.43 billion during the quarter, compared to analysts' expectations of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. On average, research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The firm also recently declared a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be issued a $1.2751 dividend. The ex-dividend date of this dividend is Monday, March 30th. This represents a yield of 708.0%. Novo Nordisk A/S's dividend payout ratio is currently 52.74%.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA approves Awiqli (insulin icodec‑abae), the first once‑weekly basal insulin for adults with type 2 diabetes — expands treatment choices, may improve adherence vs daily basal insulin and supports a U.S. launch in the second half of 2026. US FDA approves Novo's insulin injection for type 2 diabetes
• Positive Sentiment: Corporate governance/market strategy bolstered by appointment of Mars CEO Poul Weihrauch as a board observer — intended to strengthen Novo’s positioning and commercial insights in the competitive U.S. obesity market. Novo Nordisk appoints Mars CEO as board observer
• Neutral Sentiment: Filed updated Articles of Association and capital‑increase mandate — routine corporate housekeeping that can enable share issuance or compensation plans but has no immediate earnings impact. Articles of Association for Novo Nordisk A/S 2026
• Neutral Sentiment: Mixed analyst coverage: Wolfe Research started coverage with a "peer perform" rating and some brokers give neutral takes on the pipeline — underscores divergent views on growth sustainability vs valuation.
• Neutral Sentiment: Pipeline commentary: promising signals for next‑generation candidates (e.g., UBT251 triple‑agonist) but analysts flag that new oral drug trends and incremental data so far are not yet transformative. GLP‑1 pipeline shows promise but oral drug trends give analysts pause
• Negative Sentiment: Bernstein initiated coverage with an Underperform rating and a low price target, warning the company’s earnings downgrade cycle may not be over — a clear near‑term headwind for sentiment and the stock. Bernstein initiates coverage with Underperform
• Negative Sentiment: Recent headlines and analyst notes have coincided with share weakness and short‑term selling — valuation concerns (forward P/E in the low double digits vs peers) and profit‑taking after prior rallies are weighting the stock. Stock slides as market rises

Analysts Set New Price Targets

Several brokerages recently issued reports on NVO. Morgan Stanley upgraded Novo Nordisk A/S from an "underweight" rating to an "equal weight" rating and set a $40.00 price target for the company in a report on Tuesday, March 3rd. Nordea Equity Research cut Novo Nordisk A/S to a "hold" rating in a research note on Tuesday, February 24th. TD Cowen lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $42.00 target price for the company. in a research note on Tuesday, March 10th. Sanford C. Bernstein started coverage on Novo Nordisk A/S in a report on Wednesday, March 18th. They set an "outperform" rating and a $175.00 target price on the stock. Finally, BMO Capital Markets reissued a "market perform" rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. Four analysts have rated the stock with a Buy rating, nineteen have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $65.56.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.